
CardioPharma Responds to COVID-19

WILMINGTON, N.C., Mar. 30, 2020

At CardioPharma, we embrace our global community at this time of uncertainty as we confront the realities of COVID-19. While the health and welfare of patients with cardiovascular disease and their healthcare teams are foremost in our minds, our heartfelt thoughts are with all of those who are directly and indirectly affected by this pandemic.

We understand and appreciate that, especially during times like these, information is an invaluable resource which needs to be shared. Therefore, we have expanded [our website](#) specifically to include current information regarding cardiovascular disease and COVID-19. Vigilantly monitoring information updates from WHO, CDC and others, we will be sharing relevant information on an ongoing basis throughout this event.

Cardiovascular disease mortality is already recognized as a crisis of global proportions, the world's leading cause of death, making the current COVID-19 situation a pandemic within that crisis. The increasing global data published on COVID-19 shows significantly increased morbidity and mortality for those patients with pre-existing conditions of which cardiovascular disease, hypertension and diabetes top the list. This appears to be particularly critical for the developing world, where standard of care access to medications is limited. If we could mitigate these risk factors, perhaps we could help to diminish the global human tragedy and financial burden of COVID-19.

CardioPharma would like to take this opportunity to encourage everyone to understand the importance of the necessary precautions (i.e. handwashing, self-quarantining, social distancing, etc.) for your own well-being and for those in your community, thus all of us. Stay safe.

CardioPharma and its global partners welcome the opportunity to use our resources to assist with the mitigation of the cardiovascular disease epidemic amidst the present Covid-19 pandemic.

About CardioPharma

CardioPharma Inc. is a specialty pharmaceutical company focused on the development of novel cardiovascular polypills at inexpensive, generic-level prices. Our lead product (CardiaPill™) contains three of the most widely-used generic components for the prevention and treatment of cardiovascular disease. The four fixed-dose combination presentations were specifically selected to provide flexible dosing regimens that meet the needs of most patients. Our statin, ACE-inhibitor and aspirin formulations are combined in small, easy to swallow capsules designed for patient convenience and improved compliance. Pharmacokinetic data on our highest-dose formulation, and finished product stability data for up to 24 months are available. Further assistance and additional product information are also available on our website at www.cardio-pharma.com or by contacting us at info@cardio-pharma.com or calling +1.910.794.1834.



100-A Eastwood Center, Ste 117
Wilmington, NC 28403 USA
1.910.794.1826

CONTACT: CardioPharma, Dr. Daniel Gregory, +1.910.794.1834;
Media, INDIVO, Al Buscaino, +1.954.919.7000 x222

SOURCE CardioPharma, Inc.

RELATED LINKS

<http://www.cardio-pharma.com>